Bio


Sharada Kalanidhi is Director of Data Science at the Stanford Genome Technology Center (SGTC), Department of Biochemistry, Stanford University School of Medicine. Before joining Stanford, she spent more than 20 years in industry in leadership roles spanning quantitative strategy, mathematical modeling, platform development, data science, and statistics. Her multidisciplinary experience shapes her approach to biomedical research.

She spent a decade on Wall Street developing mathematical algorithms underlying pricing, trading, and portfolio strategies for complex financial instruments, including interest rate derivatives and mortgage-backed securities. She also led teams building quantitative decision-engine platforms to evaluate and manage portfolio risk under changing market conditions.

Her transition into biomedical research began when a family member developed unexplained fatigue. This experience led her to collaborate with researchers at SGTC on statistical and computational investigations of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and eventually join Stanford full-time.

Her subsequent research has included multivariate statistical and machine learning analyses of genomic, proteomic, and metabolomic data associated with ME/CFS and post-viral syndromes, including Long COVID. Her broader research interests lie at the intersection of biology, chemistry, and pure mathematics. She is an inventor on several granted U.S. patents.

Current Role at Stanford


Current Research: Mathematical Medicine

The essential challenge is not merely to solve a problem, but to discover the mathematical framework in which the problem can be understood — a perspective associated with the mathematician Alexander Grothendieck.

We spent decades using sophisticated mathematics to understand financial markets. What happens when we bring that same mathematical direction—and deeper ideas from pure mathematics—to understanding human biology?

This question captures the intellectual motivation behind Sharada's current work: developing the foundations of Mathematical Medicine, a proposed new discipline that draws on pure mathematics to address fundamental challenges in individualized diagnosis, personalized therapeutics, cancer treatments, and healthy longevity.

The work begins with a central challenge in contemporary medicine. Advances in genomics, proteomics, metabolomics, and computational biology have generated unprecedented volumes of biomedical data. Yet translating these measurements into meaningful insights for individual patients remains difficult, particularly for those with rare, complex, or previously unexplained conditions.

Conventional statistical and machine learning approaches have transformed biomedical research, but their reliance on population-level patterns can limit their usefulness when an individual patient's biology differs substantially from that of available reference cohorts. Clinically meaningful differences may be treated as statistical noise or outliers rather than investigated as potential clues to underlying disease mechanisms.

After more than a decade of research and collaboration with biochemists at SGTC, Sharada became increasingly interested in whether the mathematical foundations used to interpret biomedical data were sufficient for the complexity of individualized medicine.

Her central premise is that progress in personalized medicine may require not simply more data or larger computational models, but new mathematical ways of understanding biological systems.

Rather than applying existing statistical approaches to biomedical problems, Mathematical Medicine explores whether ideas from pure mathematics can fundamentally change how biological questions are formulated, understood, and solved.

The research is guided by the possibility that deeper mathematical understanding can reveal - and preserve- meaningful biological relationships even when data are limited, heterogeneous, or difficult to interpret using conventional approaches.

This approach echoes a perspective expressed by the mathematician Mikhail Gromov: “This area does not yet exist. It will have to be invented.”

It also reflects the empirical philosophy associated with the mathematician and quantitative investor Jim Simons: “We don't start with models. We start with data. We don't have any preconceived notions.” The aim is to allow biological observations to guide mathematical inquiry, rather than forcing them into existing computational frameworks.

Sharada's research has contributed to investigations of complex and previously unexplained clinical conditions, including cases in which mathematical and multi-omic analyses helped identify potential diagnoses and therapeutic pathways. These investigations also motivate broader questions about how individual biological differences can inform our understanding of disease.

The long-term vision is to establish Mathematical Medicine as a rigorous discipline connecting pure mathematics, molecular biology, and clinical medicine—advancing mathematics toward a foundation for understanding individual biology, preserving biological mechanisms and informing clinical decisions.

Further information about Mathematical Medicine, its research vision, and opportunities for early philanthropic partnerships is available at:

https://mathmed-2026.web.app/

Patents


  • "United States Patent 8996510 Identifying digital content using bioresponse data", Mar 31, 2015
  • "United States Patent 8719278 Method and system of scoring documents based on attributes obtained from a digital document by eye-tracking data analysis", May 6, 2014
  • "United States Patent 8509826 Biosensor measurements included in the association of context data with a text message", Aug 13, 2013

All Publications


  • Immunoglobulin G complexes from post-infectious ME/CFS, including post-COVID ME/CFS disrupt cellular energetics and alter inflammatory marker secretion. Brain, behavior, & immunity - health Liu, Z., Hollmann, C., Kalanidhi, S., Lamer, S., Schlosser, A., Basens, E. E., Nikolayshvili, G., Sokolovska, L., Riemekasten, G., Rust, R., Bellmann-Strobl, J., Paul, F., Naviaux, R. K., Nora-Krukle, Z., Sotzny, F., Scheibenbogen, C., Prusty, B. K. 2026; 52: 101187

    Abstract

    Autoimmunity is a key clinical feature in both post-infectious Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Post-Acute Sequelae of COVID (PASC). Passive transfer of immunoglobulins from patients' sera into mice induces some clinical features of PASC. However, the physiological effects of immunoglobulins on cellular alterations remain elusive. In this study, we tested the potential effects of immunoglobulins from ME/CFS patients on endothelial cell dysfunction.We have isolated immunoglobulins from 106 individuals, including ME/CFS (n = 39), PCS-CFS (n = 15), MS (n = 20) patients, and healthy controls (n = 41). Protein composition of the isolated immune complexes was studied using mass spectrometry. The effect of isolated immune complexes on mitochondria was evaluated using confocal microscopy and a Seahorse XFe96 Extracellular Flux Analyzer, and the impact on inflammatory cytokine secretion was studied using a multiplex bead-based assay.Here, we demonstrate that IgG isolated from post-infectious ME/CFS patients selectively induces mitochondrial fragmentation in human endothelial cells and alters cellular energetics. This effect is lost upon cleavage of IgG into its Fab and Fc fragments. The digested Fab fragment from ME/CFS alone was able to alter the cellular energetics, resembling the effect of intact IgG. IgG from post-infectious ME/CFS, including post-COVID ME/CFS patients, induced distinct but separate cytokine secretion profiles in healthy PBMCs. Proteomics analysis of IgG-bound immune complexes revealed significant changes in immune complexes from ME/CFS patients, affecting extracellular matrix organization, whereas those from post-COVID ME/CFS patients pointed to alterations in hemostasis and blood clot regulation.We demonstrate that IgGs from ME/CFS patients carry a chronic protective stress response that promotes mitochondrial adaptation via fragmentation, without altering mitochondrial ATP generation capacity in endothelial cells. Together, these results highlight a potential pathogenic role of IgG in post-infectious ME/CFS and point to novel therapeutic strategies targeting antibody-mediated metabolic dysregulation.

    View details for DOI 10.1016/j.bbih.2026.101187

    View details for PubMedID 41704659

    View details for PubMedCentralID PMC12907502

  • Increased circulating fibronectin, depletion of natural IgM and heightened EBV, HSV-1 reactivation in ME/CFS and long COVID. medRxiv : the preprint server for health sciences Liu, Z., Hollmann, C., Kalanidhi, S., Grothey, A., Keating, S., Mena-Palomo, I., Lamer, S., Schlosser, A., Kaiping, A., Scheller, C., Sotzny, F., Horn, A., Nürnberger, C., Cejka, V., Afshar, B., Bahmer, T., Schreiber, S., Vehreschild, J. J., Miljukov, O., Schäfer, C., Kretzler, L., Keil, T., Reese, J. P., Eichner, F. A., Schmidbauer, L., Heuschmann, P. U., Störk, S., Morbach, C., Riemekasten, G., Beyersdorf, N., Scheibenbogen, C., Naviaux, R. K., Williams, M., Ariza, M. E., Prusty, B. K. 2023

    Abstract

    Myalgic Encephalomyelitis/ Chronic Fatigue syndrome (ME/CFS) is a complex, debilitating, long-term illness without a diagnostic biomarker. ME/CFS patients share overlapping symptoms with long COVID patients, an observation which has strengthened the infectious origin hypothesis of ME/CFS. However, the exact sequence of events leading to disease development is largely unknown for both clinical conditions. Here we show antibody response to herpesvirus dUTPases, particularly to that of Epstein-Barr virus (EBV) and HSV-1, increased circulating fibronectin (FN1) levels in serum and depletion of natural IgM against fibronectin ((n)IgM-FN1) are common factors for both severe ME/CFS and long COVID. We provide evidence for herpesvirus dUTPases-mediated alterations in host cell cytoskeleton, mitochondrial dysfunction and OXPHOS. Our data show altered active immune complexes, immunoglobulin-mediated mitochondrial fragmentation as well as adaptive IgM production in ME/CFS patients. Our findings provide mechanistic insight into both ME/CFS and long COVID development. Finding of increased circulating FN1 and depletion of (n)IgM-FN1 as a biomarker for the severity of both ME/CFS and long COVID has an immediate implication in diagnostics and development of treatment modalities.

    View details for DOI 10.1101/2023.06.23.23291827

    View details for PubMedID 37425897

    View details for PubMedCentralID PMC10327231

  • Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole. Journal of translational medicine Crosby, L. D., Kalanidhi, S., Bonilla, A., Subramanian, A., Ballon, J. S., Bonilla, H. 2021; 19 (1): 50

    View details for DOI 10.1186/s12967-021-02721-9

    View details for PubMedID 33536023